1.87

3.11% -0.06

Pre-market: 1.88 0.010 +0.53%

Iovance Biotherapeutics Inc (IOVA)

Overview News Price History Option Chain Financials Why IOVA Down? Discussions Forecast Stock Split

Iovance Biotherapeutics Inc stock is traded at $1.87, with a volume of 6.77M. It is down -3.11% in the last 24 hours and down -16.52% over the past month. Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Previous Close:

$1.93

Open:

$1.9

24h Volume:

6.77M

Relative Volume:

0.51

Market Cap:

$794.76M

Revenue:

$32.77M

Net Income/Loss:

$-440.22M

P/E Ratio:

-1.1198

EPS:

-1.67

Net Cash Flow:

$-400.48M

1W Performance:

+6.86%

1M Performance:

-16.52%

6M Performance:

-70.78%

1Y Performance:

-77.84%

1-Day Range:

$1.85

$1.93

1-Week Range:

$1.68

$2.02

52-Week Range:

$1.6385

$12.51

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Name

Iovance Biotherapeutics Inc

Sector

Healthcare (1164)

Industry

Biotechnology (655)

Phone

(650) 260-7120

Address

825 INDUSTRIAL ROAD, SAN CARLOS

Employee

838

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

IOVA's Discussions on Twitter

Compare IOVA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IOVA Iovance Biotherapeutics Inc	1.87	794.76M	32.77M	-440.22M	-400.48M	-1.67
VRTX Vertex Pharmaceuticals Inc	468.85	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	567.74	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	314.94	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	560.24	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	250.30	28.51B	3.81B	-644.79M	-669.77M	-6.24

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-16-25	Downgrade	UBS	Buy → Neutral
May-12-25	Downgrade	Truist	Buy → Hold
May-09-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Oct-24-24	Initiated	UBS	Buy
Jul-29-24	Downgrade	Piper Sandler	Overweight → Neutral
Nov-20-23	Initiated	Goldman	Buy
Sep-18-23	Reiterated	Barclays	Overweight
May-30-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Mar-27-23	Resumed	Wells Fargo	Equal Weight
Jan-27-23	Upgrade	Piper Sandler	Neutral → Overweight
Dec-09-22	Downgrade	Goldman	Buy → Neutral
Oct-31-22	Initiated	Guggenheim	Neutral
Aug-18-22	Resumed	Wells Fargo	Equal Weight
Jan-28-22	Upgrade	Stifel	Hold → Buy
Dec-07-21	Resumed	Cowen	Outperform
Jun-10-21	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
May-20-21	Downgrade	Piper Sandler	Overweight → Neutral
May-19-21	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
May-19-21	Downgrade	Stifel	Buy → Hold
May-03-21	Initiated	Truist	Buy
Apr-16-21	Initiated	Goldman	Buy
Mar-08-21	Upgrade	H.C. Wainwright	Neutral → Buy
Dec-15-20	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-06-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-22-20	Initiated	Mizuho	Buy
Mar-04-20	Initiated	Barclays	Overweight
Feb-26-20	Reiterated	H.C. Wainwright	Buy
Feb-26-20	Reiterated	Oppenheimer	Outperform
Dec-18-19	Initiated	JMP Securities	Mkt Outperform
Oct-01-19	Initiated	Stifel	Buy
Apr-29-19	Initiated	Piper Jaffray	Overweight
Feb-28-19	Reiterated	Chardan Capital Markets	Buy
Feb-07-19	Initiated	Robert W. Baird	Outperform
Dec-31-18	Resumed	B. Riley FBR	Buy
Jul-06-18	Reiterated	Chardan Capital Markets	Buy
Apr-10-18	Upgrade	B. Riley FBR, Inc.	Neutral → Buy
Mar-13-18	Reiterated	B. Riley FBR, Inc.	Neutral
Feb-23-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
Jan-25-18	Reiterated	H.C. Wainwright	Buy
Nov-01-17	Reiterated	B. Riley FBR, Inc.	Buy

View All

Iovance Biotherapeutics Inc Stock (IOVA) Latest News

04:57 AM

Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Join Class Action Before July 14, 2025Contact Levi & Korsinsky - ACCESS Newswire

04:57 AM

03:49 AM

IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener

03:49 AM

Jul 13, 2025

IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire

Jul 13, 2025

IOVA Deadline: IOVA Investors with Losses in Excess of $100K Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit - PR Newswire

Jul 13, 2025

2025-07-13 | Investor Alert: Deadline Approaching to Join Iovance Biotherapeutics, Inc. (IOVA) Class ActionContact Levi & Korsinsky | NDAQ:IOVA | Press Release - Stockhouse

Jul 13, 2025

Iovance Biotherapeutics Sued for Securities Law ViolationsInvestors Should Contact Faruqi & Faruqi for More InformationIOVA - StreetInsider

Jul 13, 2025

Jul 12, 2025

IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire

Jul 12, 2025

IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Iovance Biotherapeutics, Inc. and Urgently Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Jul 12, 2025

IOVA FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important July 14 Deadline in Securities Class Action – IOVA - TradingView

Jul 12, 2025

IOVA 2-DAY DEADLINE ALERT: Iovance’s (IOVA) CFO Resigns - GlobeNewswire

Jul 12, 2025

IOVA FRAUD ALERT: Iovance Biotherapeutics 44% Stock Drop - GlobeNewswire

Jul 12, 2025

Jul 11, 2025